Gan & Lee Pharmaceuticals Hits Day Low Amid Price Pressure, Stock at CNY 64.18

Gan & Lee Pharmaceuticals Co., Ltd. experienced a significant decline today, with the stock dropping by 7.39% and reaching an intraday low of CNY 64.18. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.05% on the same day. Over the past week, Gan & Lee's stock has decreased by 3.31%, while it has shown a more favorable performance over the past month, gaining 18.84%. Year-to-date, the stock has seen a decline of 5.58%, slightly underperforming the China Shanghai Composite, which is down 5.16%. However, the company has demonstrated resilience over a longer time frame, with a notable 56.49% increase over the past three years. Despite the recent downturn, Gan & Lee has reported positive results for the last eight consecutive quarters, with net sales growing by 23% in the first half of the year. The company maintains a strong return on capital employed (ROCE) of 8.23% and a high dividend yield of 1.8%. However, concerns about long-term growth persist, as evidenced by a modest annual net sales growth rate of 3.44% over the last five years.